Am I a candidate for BHRT?
Candidacy depends on symptoms, biomarkers, time since menopause onset, and personal/family breast, cardiovascular, and thrombotic history. A provider review confirms candidacy and selects modality, dose, and progesterone strategy.
Full answer
BHRT candidacy is established through the assessment, the baseline biomarker panel, and a synchronous video review with a licensed provider. The decision integrates symptoms (vasomotor, sleep, mood, cognition, libido, genitourinary), biomarkers, time since menopause onset (the 'window of opportunity'), personal/family breast cancer history, cardiovascular history, and venous thromboembolism risk. Disqualifying conditions include active estrogen-sensitive cancer, recent thromboembolism, active liver disease, and undiagnosed vaginal bleeding. Modality (transdermal vs oral), dose, and progesterone strategy are selected by the provider.
Educational. Not a substitute for individualized provider review.
- BHRT Optimization pathway — Primary source · oMeds
- Reviewed by Dr. Laura Purdy, MD, MBA · Clinical Director, oMeds · Last reviewed 2026-06-03